fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

DURECT Corporation to highlight new data on Larsucosterol for alcohol-associated hepatitis at The Liver Meeting 2024

Written by | 21 Oct 2024 | Conference Highlights

DURECT Corporation a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce that it will deliver an oral and two poster presentations at The Liver Meeting 2024, organized by the American Association for the Study of Liver Diseases (AASLD), to be held November 15-19, 2024 in San Diego, California.

The presentations will showcase additional data from DURECT’s completed Phase 2b trial evaluating its lead asset, larsucosterol, for the treatment of alcohol-associated hepatitis (AH). The data further support the design of the Company’s upcoming Phase III trial of larsucosterol in AH, including the importance of timely treatment in clinical outcomes.

Presentation details are as follow:

Oral Presentation:

Title: Effects of Timely Treatment on Outcomes of Larsucosterol for Severe Alcohol-associated Hepatitis (AHFIRM Trial)
Presentation Number: 198
Session: Abstract Parallel Sessions – PBC, Alcohol-associated Hepatitis, Hepatitis B, Portal Hypertension, Costs of Care
Date and Time: November 18, 12:15 – 12:30 pm PT
Presenter: Lance Stein, Piedmont Healthcare, Atlanta, GA, USA

Poster Presentations:

Title: A Balancing Act: The Life-Saving Potential and Ethical Dilemmas of Liver Transplantation as an Endpoint in Alcohol Associated Hepatitis Trials
Presentation Number: 3040
Session: Abstract Poster – Alcohol-Associated Liver Diseases: Clinical and Experimental
Date and Time: November 17, 1:00 PM-2:00 PM (posters will be available from 8:00 AM – 5:00 PM PT)
Presenter: Aparna Goel, Stanford University Medical Center, Stanford, CA, U.S.

Title: Drinking Behavior in the AHFIRM trial as measured by Phosphatidyl Ethanol
Presentation Number: 3140
Session: Abstract Poster – Alcohol-Associated Liver Diseases: Clinical and Experimental
Date and Time: November 17, 1:00 PM-2:00 PM (posters will be available from 8:00 AM – 5:00 PM PT)
Presenter: Steven Flamm, Rush University, Chicago, IL, U.S.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.